No Data
Top Premarket Decliners
Why BloomZ Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket
LifeSci Capital Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Maintains Target Price $8
LifeSci Capital Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Maintains Target Price $8
LifeSci Capital analyst Charles Zhu maintains $Mersana Therapeutics(MRSN.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 37.3
Buy Rating for Mersana Therapeutics: Promising ADC Developments and Strategic Market Positioning
Truist Financial Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Announces Target Price $9
Truist Financial analyst Asthika Goonewardene maintains $Mersana Therapeutics(MRSN.US)$ with a buy rating, and sets the target price at $9.According to TipRanks data, the analyst has a success rate
No Data
No Data